[1]胡志强,王先正,姜艳红.止痛益气汤联合腹腔化疗治疗HBeAg阳性肝癌疗效及对患者肝功能的影响[J].陕西中医,2021,(5):573-576.[doi:DOI:10.3969/j.issn.1000-7369.2020.05.007]
　HU Zhiqiang,WANG Xianzheng,JIANG Yanhong.Clinical effect of Zhitong Yiqi decoction combined with peritoneal chemotherapy on HBeAg positive hepatocellular carcinoma and its effect on liver function[J].,2021,(5):573-576.[doi:DOI:10.3969/j.issn.1000-7369.2020.05.007]
点击复制

止痛益气汤联合腹腔化疗治疗HBeAg阳性肝癌疗效及对患者肝功能的影响

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2021年5期
页码:
573-576
栏目:
临床研究
出版日期:
2021-05-05

文章信息/Info

Title:
Clinical effect of Zhitong Yiqi decoction combined with peritoneal chemotherapy on HBeAg positive hepatocellular carcinoma and its effect on liver function
作者:
胡志强1; 王先正1; 姜艳红2
(1.海南省肿瘤医院中医科,海南 海口 570311; 2.郑州大学附属肿瘤医院检验科,河南 郑州 450008)
Author(s):
HU Zhiqiang; WANG Xianzheng; JIANG Yanhong
(Chinese Medicine Department,Hainan Cancer Hospital,Haikou 570311,China)
关键词:
HBeAg阳性肝癌;  止痛益气汤;  腹腔化疗;  外周血淋巴细胞亚群;  肝功能
Keywords:
HBeAg positive liver cancer;  Zhitong Yiqi decoction;  Abdominal chemotherapy;  Peripheral blood lymphocyte subsets;  Liver function
分类号:
R 735.7
DOI:
DOI:10.3969/j.issn.1000-7369.2020.05.007
文献标志码:
A
摘要:
目的:探讨止痛益气汤联合腹腔化疗治疗HBeAg阳性肝癌的临床疗效及对患者肝功能的影响。方法:将96例HBeAg阳性患者随机分为对照组与观察组。对照组仅给予腹腔化疗治疗,观察组联合止痛益气汤治疗。比较两组患者治疗前后中医症候积分、外周血T淋巴细胞亚群水平及肝功能水平。结果:观察组治疗后中医症候积分均显著大于对照组(均P<0.05); 观察组治疗后CD3+、CD4+及CD4+/CD8+水平均显著高于治疗前及对照组治疗后(均P<0.05),观察组治疗后CD8+水平显著低于治疗前及对照组治疗后(均P<0.05); 观察组患者治疗后肝功能相关指标(ALT、AST及TBIL)水平均显著低于对照组(均P<0.05); 观察组治疗效果显著优于对照组(P<0.05)。结论:止痛益气汤联合腹腔化疗治疗HBeAg阳性肝癌的疗效显著,可改善患者外周血淋巴细胞亚群水平及肝功能水平。
Abstract:
Objective:Investigate the clinical effect of Zhitong Yiqi decoction combined with peritoneal chemotherapy on HBeAg positive liver cancer and its effect on liver function.Methods:A total of 96 HBeAg-positive patients were randomly divided into control group and observation group.The control group was treated with intraperitoneal chemotherapy only,while the observation group was treated with Zhitong Yiqi decoction.The scores of TCM syndromes,T lymphocyte subsets in peripheral blood and liver function of the two groups were compared before and after treatment.Results:The scores of TCM syndromes the post-treatment in the observation were significantly lower than the scores of the post-treatment in the control(all P<0.05).After treatment,the levels of CD3+,CD4+ and CD4+/CD8+ of the observation group were significantly higher than before and after treatment of the control group(all P<0.05),and the CD8+ was on the contrary between the two groups(P<0.05).After treatment,the levels of liver function related indicators(ALT,AST and TBIL)of the observation group were significantly lower than the control group(all P<0.05).The treatment effect of the observation group was better than the control group(P<0.05).Conclusion:Zhitong Yiqi decoction combined with peritoneal chemotherapy has a significant effect on HBeAg positive liver cancer,and can improve the level of peripheral blood lymphocyte subsets and liver function in patients,which should be promoted and applied.

参考文献/References:

[1] 徐海虹,周旭东,冯 锦,等.益气健脾疏肝汤对乳腺癌术后化疗患者细胞免疫功能的影响[J].中国中医药科技,2014,21(3):306-307.
[2] 张 俊,张金生.益脾活瘀汤治疗乙型肝炎肝硬变30例[J].河南中医,2017,37(2):251-253.
[3] Boglione L,Cusato J,Allegra S,et al.Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon [J].Antiviral Res,2014,102(13):35-43.
[4] 黄 丹,孙定隆,王 敏,等.扶脾柔肝汤治疗肝硬化40例临床报道[J].贵阳中医学院学报,2015,37(5):51-53.
[5] 刘文君,陈向峰,何淑宏,等.恩替卡韦联合软肝缩脾汤治疗肝硬化脾功能亢进的临床观察[J].河北医药,2014,25(17):2662-2663.
[6] 李卓伟.八珍汤对原发性肝癌介入治疗术后不良反应的干预及临床疗效[J].现代诊断与治疗,2017,28(20):3773-3775.
[7] 胡若冰,杨玉秀.替吉奥与肝动脉化疗栓塞术联合治疗BCLCB期原发性肝癌的临床效果[J].中国疗养医学,2018,27(6):656-658.
[8] 杨学宁,吴一龙.实体瘤治疗疗效评价标准(RECIST)[J].循证医学,2004,4(2):85-90.
[9] 池丽芬.顺铂腹腔热灌注化疗与其他用药方式药代动力学比较[J].实用肿瘤学杂志,2000,15(3):179-181.
[10] 张 振,郜文辉,王亚琪,等.益气化瘀解毒方加减联合索拉非尼治疗原发性肝癌疗效研究[J].陕西中医,2019,40(3):322-324.
[11] 王邦才,刘 帆,柯春海,等.健脾消瘤合剂对中晚期原发性肝癌的临床疗效观察[J].浙江中医药大学学报,2014,38(12):1404-1407.
[12] 刘文导,梅世伟,孟凡喆,等.健脾补肾方联合针灸治疗对原发性肝癌肝动脉化疗栓塞术后综合征细胞免疫功能的调节[J].吉林中医药,2014,34(12):1222-1224.
[13] Na ML,Chun DX,Yan LX,et al.De novo combination therapy adefovir plus lamivudine as a treatment for women of child-bearing age with HBeAg-positive chronic hepatitis B before pregnancy[J].Journal of Medical Virology,2014,86(3):433-436.
[14] 曾祥源,孙克伟.乙肝肝硬化抗病毒治疗期间进展为原发性肝癌35例临床分析[J].医学临床研究,2016,23(1):180-181.
[15] 赵 川,陈 虹,范铁艳,等.HBeAg 阴性乙型肝炎未经治疗表面抗原转阴并发展至肝硬化肝癌行肝移植1例[J].肝脏,2016,21(3):235-236.
[16] 占春玲.乙肝肝硬化并发原发性肝癌危险因素的logistic回归分析[J].医学临床研究,2016,33(9):1697-1701.
[17] Tseng TC,Liu CJ,Yang WT,et al.Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters[J].Journal of Gastroenterology and Hepatology,2014,29(6):1242-1249.
[18] 刘杰峰,金国贤,陈 刚,等.软肝缩脾汤联合恩替卡韦治疗乙型肝炎肝硬化49例[J].中西医结合肝病杂志,2016,26(1):51-52.
[19] Liu H,Wang X,Wan G,et al.Telbivudine versus entecavir for nucleos(t)ide-naive hbeag-positive chronic hepatitis B:A meta-analysis[J].The American Journal of the Medical Sciences,2014,347(2):131-138.
[20] 王雁翔,臧金旺,傅志泉,等.强化行为干预结合补肾益脾法治疗非酒精性脂肪性肝炎的临床研究[J].中西医结合肝病杂志,2016,26(2):76-78.

备注/Memo

备注/Memo:
基金项目:河南省医学科技攻关项目(201503192)
更新日期/Last Update: 2021-05-10